Ondansetron Orally Disintegrating Tablets, USP

ONDANSETRON  - ondansetron tablet, orally disintegrating 
Aurobindo Pharma Limited

----------

Ondansetron Orally Disintegrating Tablets, USP

DESCRIPTION


The active ingredient in ondansetron orally disintegrating tablets, USP is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one. It has the following structural formula:
 
Chemical Structure
 
The molecular formula is C18H19N3O representing a molecular weight of 293.4. Ondansetron is a white to off-white powder.
 
Each 4 mg ondansetron orally disintegrating tablet, USP for oral administration contains 4 mg ondansetron base. Each 8 mg ondansetron orally disintegrating tablet, USP for oral administration contains 8 mg ondansetron base. Each ondansetron orally disintegrating tablet also contains the inactive ingredients mannitol, crospovidone, lactose monohydrate, microcrystalline cellulose, aspartame, strawberry guarana flavor, colloidal silicon dioxide, and magnesium stearate. The strawberry guarana flavor contains maltodextrin, propylene glycol, artificial flavors, and acetic acid. Ondansetron orally disintegrating tablets, USP are orally administered formulation of ondansetron which rapidly disintegrates on the tongue and does not require water to aid dissolution or swallowing.

This product does not meet USP Disintegration Time. The 4 mg and 8 mg tablets disintegrate in approximately 60 seconds.

CLINICAL PHARMACOLOGY

Pharmacodynamics


Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron’s antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine. In humans, urinary 5-HIAA (5-hydroxyindoleacetic acid) excretion increases after cisplatin administration in parallel with the onset of emesis. The released serotonin may stimulate the vagal afferents through the 5-HT3 receptors and initiate the vomiting reflex.
 
In animals, the emetic response to cisplatin can be prevented by pretreatment with an inhibitor of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic nerve section, or pretreatment with a serotonin 5-HT3 receptor antagonist.
 
In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations.

Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied.

Pharmacokinetics


Ondansetron is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism. Mean bioavailability in healthy subjects, following administration of a single 8 mg tablet, is approximately 56%.
 
Ondansetron systemic exposure does not increase proportionately to dose. AUC from a 16 mg tablet was 24% greater than predicted from an 8 mg tablet dose. This may reflect some reduction of first-pass metabolism at higher oral doses. Bioavailability is also slightly enhanced by the presence of food but unaffected by antacids.
 
Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.

In vitro
metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination. Ondansetron elimination may be affected by cytochrome P-450 inducers. In a pharmacokinetic study of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, reduction in AUC, Cmax, and T½ of ondansetron was observed.1 This resulted in a significant increase in clearance. However, on the basis of available data, no dosage adjustment for ondansetron is recommended (see PRECAUTIONS: Drug Interactions).
 
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
 
Gender differences were shown in the disposition of ondansetron given as a single dose. The extent and rate of ondansetron's absorption is greater in women than men. Slower clearance in women, a smaller apparent volume of distribution (adjusted for weight), and higher absolute bioavailability resulted in higher plasma ondansetron levels. These higher plasma levels may in part be explained by differences in body weight between men and women. It is not known whether these gender-related differences were clinically important. More detailed pharmacokinetic information is contained in Tables 1 and 2 taken from 2 studies.

Table 1. Pharmacokinetics in Normal Volunteers: Single 8 mg Ondansetron Hydrochloride Tablet Dose
Age-group
(years)
Mean Weight
(kg)
   n    Peak Plasma
Concentration
(ng/mL)
Time of Peak
Plasma
Concentration
(h)
Mean Elimination
Half-life
(h)
Systemic
Plasma Clearance
L/h/kg
Absolute
Bioavailability
18-40 M
69
6
26.2
2
3.1
0.403
0.483
F
62.7
5
42.7
1.7
3.5
0.354
0.663
 61-74 M
77.5
6
24.1
2.1
4.1
0.384
0.585
 F
60.2
6
52.4
1.9
4.9
0.255
0.643
≥75 M
78
5
37
2.2
4.5
0.277
0.619
F
67.6
6
46.1
2.1
6.2
0.249
0.747

Table 2. Pharmacokinetics in Normal Volunteers: Single 24 mg Ondansetron Hydrochloride Tablet Dose
Age-group
(years)
Mean Weight
(kg)
   n   Peak Plasma
Concentration
(ng/mL)
Time of Peak
Plasma Concentration
(h)
Mean Elimination
Half-life
(h)
18-43 M
84.1
8
125.8
1.9
4.7
F
71.8
8
194.4
1.6
5.8

A reduction in clearance and increase in elimination half-life are seen in patients over 75 years of age. In clinical trials with cancer patients, safety and efficacy were similar in patients over 65 years of age and those under 65 years of age; there was an insufficient number of patients over 75 years of age to permit conclusions in that age-group. No dosage adjustment is recommended in the elderly.
 
In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals. In patients with severe hepatic impairment (Child-Pugh2 score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours. In patients with severe hepatic impairment, a total daily dose of 8 mg should not be exceeded.
 
Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron oral mean plasma clearance was reduced by about 50% in patients with severe renal impairment (creatinine clearance <30 mL/min). This reduction in clearance is variable and was not consistent with an increase in half-life. No reduction in dose or dosing frequency in these patients is warranted.
 
Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes.

Four and 8 mg doses of either ondansetron oral solution or ondansetron orally disintegrating tablets are bioequivalent to corresponding doses of ondansetron hydrochloride tablets and may be used interchangeably. One 24 mg ondansetron hydrochloride tablet is bioequivalent to and interchangeable with three 8 mg ondansetron hydrochloride tablets.

Clinical Trials

Chemotherapy-Induced Nausea and Vomiting

Highly Emetogenic Chemotherapy


In 2 randomized, double-blind, monotherapy trials, a single 24 mg ondansetron hydrochloride tablet was superior to a relevant historical placebo control in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2. Steroid administration was excluded from these clinical trials. More than 90% of patients receiving a cisplatin dose ≥50 mg/m2 in the historical placebo comparator experienced vomiting in the absence of antiemetic therapy.
 
The first trial compared oral doses of ondansetron 24 mg once a day, 8 mg twice a day, and 32 mg once a day in 357 adult cancer patients receiving chemotherapy regimens containing cisplatin ≥50 mg/m2. A total of 66% of patients in the ondansetron 24 mg once-a-day group, 55% in the ondansetron 8 mg twice-a-day group, and 55% in the ondansetron 32 mg once-a-day group completed the 24-hour study period with 0 emetic episodes and no rescue antiemetic medications, the primary endpoint of efficacy. Each of the 3 treatment groups was shown to be statistically significantly superior to a historical placebo control.
 
In the same trial, 56% of patients receiving oral ondansetron 24 mg once a day experienced no nausea during the 24-hour study period, compared with 36% of patients in the oral ondansetron 8 mg twice-a-day group (P = 0.001) and 50% in the oral ondansetron 32 mg once-a-day group.

In a second trial, efficacy of the oral ondansetron 24 mg once-a-day regimen in the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2, was confirmed.

Moderately Emetogenic Chemotherapy


In 1 double-blind U.S. study in 67 patients, ondansetron hydrochloride tablets 8 mg administered twice a day were significantly more effective than placebo in preventing vomiting induced by cyclophosphamide-based chemotherapy containing doxorubicin. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized in Table 3:
Table 3. Emetic Episodes: Treatment Response
 Ondansetron
8 mg b.i.d.
Ondansetron
Hydrochloride Tablets*
PlaceboP Value
* The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8 mg ondansetron hydrochloride tablet was administered twice a day for 2 days after completion of chemotherapy.
Median undefined since at least 50% of the patients were withdrawn or had more than 2 emetic episodes.
Median undefined since at least 50% of patients did not have any emetic episodes.
   Number of patients
33
34
   Treatment response
      0 Emetic episodes
20 (61%)
2 (6%)
<0.001
      1 to 2 Emetic episodes
6 (18%)
8 (24%)
   More than 2 emetic episodes/withdrawn
7 (21%)
24 (71%)
<0.001
   Median number of emetic episodes
0
Undefined
   Median time to first emetic episode (h)
Undefined
6.5

In 1 double-blind U.S. study in 336 patients, ondansetron hydrochloride tablets 8 mg administered twice a day were as effective as ondansetron hydrochloride tablets 8 mg administered 3 times a day in preventing nausea and vomiting induced by cyclophosphamide-based chemotherapy containing either methotrexate or doxorubicin. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized in Table 4:
Table 4. Emetic Episodes: Treatment Response
Ondansetron
8 mg b.i.d.
Ondansetron
Hydrochloride
Tablets*
8 mg t.i.d.
Ondansetron
Hydrochloride
Tablets†
* The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8 mg ondansetron hydrochloride tablet was administered twice a day for 2 days after completion of chemotherapy.
The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. An 8 mg ondansetron hydrochloride tablet was administered 3 times a day for 2 days after completion of chemotherapy.
Median undefined since at least 50% of patients did not have any emetic episodes.
§ Visual analog scale assessment: 0 = no nausea, 100 = nausea as bad as it can be.
   Number of patients
165
171
   Treatment response
      0 Emetic episodes
101 (61%)
99 (58%)
      1 to 2 Emetic episodes
16 (10%)
17 (10%)
      More than 2 emetic episodes/withdrawn
48 (29%)
55 (32%)
   Median number of emetic episodes
0
0
   Median time to first emetic episode (h)
Undefined
Undefined
   Median nausea scores (0 to 100)§
6
6

Re-treatment


In uncontrolled trials, 148 patients receiving cyclophosphamide-based chemotherapy were re-treated with ondansetron hydrochloride tablets 8 mg 3 times daily during subsequent chemotherapy for a total of 396 re-treatment courses. No emetic episodes occurred in 314 (79%) of the re-treatment courses, and only 1 to 2 emetic episodes occurred in 43 (11%) of the re-treatment courses.

Pediatric Studies


Three open-label, uncontrolled, foreign trials have been performed with 182 pediatric patients 4 to 18 years old with cancer who were given a variety of cisplatin or noncisplatin regimens. In these foreign trials, the initial dose of ondansetron hydrochloride injection ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg. This was followed by the administration of ondansetron hydrochloride tablets ranging from 4 to 24 mg daily for 3 days. In these studies, 58% of the 170 evaluable patients had a complete response (no emetic episodes) on day 1. Two studies showed the response rates for patients less than 12 years of age who received ondansetron hydrochloride tablets 4 mg 3 times a day to be similar to those in patients 12 to 18 years of age who received ondansetron hydrochloride tablets 8 mg 3 times daily. Thus, prevention of emesis in these pediatric patients was essentially the same as for patients older than 18 years of age. Overall, ondansetron hydrochloride tablets were well tolerated in these pediatric patients.

Radiation-Induced Nausea and Vomiting

Total Body Irradiation


In a randomized, double-blind study in 20 patients, ondansetron hydrochloride tablets (8 mg given 1.5 hours before each fraction of radiotherapy for 4 days) were significantly more effective than placebo in preventing vomiting induced by total body irradiation. Total body irradiation consisted of 11 fractions (120 cGy per fraction) over 4 days for a total of 1,320 cGy. Patients received 3 fractions for 3 days, then 2 fractions on day 4.

Single High-Dose Fraction Radiotherapy


Ondansetron was significantly more effective than metoclopramide with respect to complete control of emesis (0 emetic episodes) in a double-blind trial in 105 patients receiving single high-dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of ≥80 cm2 to the abdomen. Patients received the first dose of ondansetron hydrochloride tablets (8 mg) or metoclopramide (10 mg) 1 to 2 hours before radiotherapy. If radiotherapy was given in the morning, 2 additional doses of study treatment were given (1 tablet late afternoon and 1 tablet before bedtime). If radiotherapy was given in the afternoon, patients took only 1 further tablet that day before bedtime. Patients continued the oral medication on a 3 times a day basis for 3 days.

Daily Fractionated Radiotherapy


Ondansetron was significantly more effective than prochlorperazine with respect to complete control of emesis (0 emetic episodes) in a double-blind trial in 135 patients receiving a 1- to 4-week course of fractionated radiotherapy (180 cGy doses) over a field size of ≥100 cm2 to the abdomen. Patients received the first dose of ondansetron hydrochloride tablets (8 mg) or prochlorperazine (10 mg) 1 to 2 hours before the patient received the first daily radiotherapy fraction, with 2 subsequent doses on a 3 times a day basis. Patients continued the oral medication on a 3 times a day basis on each day of radiotherapy.

Postoperative Nausea and Vomiting


Surgical patients who received ondansetron 1 hour before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil, sufentanil, morphine, or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare or gallamine and/or vecuronium, pancuronium, or atracurium; and supplemental isoflurane or enflurane) were evaluated in 2 double-blind studies (1 U.S. study, 1 foreign) involving 865 patients. Ondansetron hydrochloride tablets (16 mg) were significantly more effective than placebo in preventing postoperative nausea and vomiting.

The study populations in all trials thus far consisted of women undergoing inpatient surgical procedures. No studies have been performed in males. No controlled clinical study comparing ondansetron hydrochloride tablets to ondansetron hydrochloride injection has been performed.

INDICATIONS AND USAGE

 

  1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2.
  2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
  3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.
  4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low.

CONTRAINDICATIONS


The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.
 
Ondansetron orally disintegrating tablets are contraindicated for patients known to have hypersensitivity to the drug.

WARNINGS


Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.

PRECAUTIONS

General


Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT interval prolongation have been reported.

Information for Patients

Phenylketonurics


Phenylketonuric patients should be informed that ondansetron orally disintegrating tablets contain phenylalanine (a component of aspartame). Each 4 mg orally disintegrating tablet contains 1.68 mg phenylalanine and 8 mg orally disintegrating tablet contains 3.37 mg phenylalanine.

Patients should be instructed not to remove ondansetron orally disintegrating tablets from the blister or from the bottle until just prior to dosing. The tablet should not be pushed through the foil. With dry hands, remove the tablet from the bottle or the blister backing should be peeled completely off the blister. The tablet should be gently removed and immediately placed on the tongue to dissolve and be swallowed with the saliva. Peelable illustrated stickers are affixed to the product carton that can be provided with the prescription to ensure proper use and handling of the product.

Drug Interactions


Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of available data, no dosage adjustment is recommended for patients on these drugs.
 
Apomorphine 

Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, concomitant use of apomorphine with ondansetron is contraindicated (see CONTRAINDICATIONS).

Phenytoin, Carbamazepine, and Rifampicin


In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3

Tramadol


Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5

Chemotherapy


Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.

In a crossover study in 76 pediatric patients, I.V. ondansetron did not increase blood levels of high-dose methotrexate.

Use in Surgical Patients


The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.

Carcinogenesis, Mutagenesis, Impairment of Fertility


Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg/day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of ondansetron up to 15 mg/kg/day did not affect fertility or general reproductive performance of male and female rats.

Pregnancy

Teratogenic Effects

Pregnancy Category B


Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg/day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers


Ondansetron is excreted in the breast milk of rats. It is not known whether ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ondansetron is administered to a nursing woman.

Pediatric Use


Little information is available about dosage in pediatric patients 4 years of age or younger (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections for use in pediatric patients 4 to 18 years of age).

Geriatric Use


Of the total number of subjects enrolled in cancer chemotherapy-induced and postoperative nausea and vomiting in U.S.- and foreign-controlled clinical trials, for which there were subgroup analyses, 938 were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment is not needed in patients over the age of 65 (see CLINICAL PHARMACOLOGY).

ADVERSE REACTIONS


The following have been reported as adverse events in clinical trials of patients treated with ondansetron, the active ingredient of ondansetron orally disintegrating tablets. A causal relationship to therapy with ondansetron has been unclear in many cases.

Chemotherapy-Induced Nausea and Vomiting


The adverse events in Table 5 have been reported in ≥5% of adult patients receiving a single 24 mg ondansetron hydrochloride tablet in 2 trials. These patients were receiving concurrent highly emetogenic cisplatin-based chemotherapy regimens (cisplatin dose  ≥50 mg/m2).

Table 5. Principal Adverse Events in U.S. Trials: Single Day Therapy With 24 mg Ondansetron Hydrochloride Tablets (Highly Emetogenic Chemotherapy)
EventOndansetron
24 mg q.d.
n = 300
Ondansetron
8 mg b.i.d.
n = 124
Ondansetron
32 mg q.d.
n = 117
   Headache
33 (11%)
16 (13%)
17 (15%)
   Diarrhea
13 (4%)
9 (7%)
3 (3%)
The adverse events in Table 6 have been reported in ≥5% of adults receiving either 8 mg of ondansetron hydrochloride tablets 2 or 3 times a day for 3 days or placebo in 4 trials. These patients were receiving concurrent moderately emetogenic chemotherapy, primarily cyclophosphamide-based regimens.
Table 6. Principal Adverse Events in U.S. Trials: 3 Days of Therapy With 8 mg Ondansetron Hydrochloride Tablets (Moderately Emetogenic Chemotherapy)
EventOndansetron
8 mg b.i.d.
n = 242
Ondansetron
8 mg t.i.d.
n = 415
Placebo
n = 262
   Headache
58 (24%)
113 (27%)
34 (13%)
   Malaise/fatigue
32 (13%)
37 (9%)
6 (2%)
   Constipation
22 (9%)
26 (6%)
1 (<1%)
   Diarrhea
15 (6%)
16 (4%)
10 (4%)
   Dizziness
13 (5%)
18 (4%)
12 (5%)

Central Nervous System


There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving ondansetron.

Hepatic


In 723 patients receiving cyclophosphamide-based chemotherapy in U.S. clinical trials, AST and/or ALT values have been reported to exceed twice the upper limit of normal in approximately 1% to 2% of patients receiving ondansetron hydrochloride tablets. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. The role of cancer chemotherapy in these biochemical changes cannot be clearly determined.

There have been reports of liver failure and death in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear.

Integumentary


Rash has occurred in approximately 1% of patients receiving ondansetron.

Other


Rare cases of anaphylaxis, bronchospasm, tachycardia, angina (chest pain), hypokalemia, electrocardiographic alterations, vascular occlusive events, and grand mal seizures have been reported. Except for bronchospasm and anaphylaxis, the relationship to ondansetron was unclear.

Radiation-Induced Nausea and Vomiting


The adverse events reported in patients receiving ondansetron hydrochloride tablets and concurrent radiotherapy were similar to those reported in patients receiving ondansetron hydrochloride tablets and concurrent chemotherapy. The most frequently reported adverse events were headache, constipation, and diarrhea.

Postoperative Nausea and Vomiting


The adverse events in Table 7 have been reported in ≥5% of patients receiving ondansetron hydrochloride tablets at a dosage of 16 mg orally in clinical trials. With the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. These patients were receiving multiple concomitant perioperative and postoperative medications.

Table 7. Frequency of Adverse Events From Controlled Studies With Ondansetron Hydrochloride Tablets (Postoperative Nausea and Vomiting)
Adverse EventOndansetron 16 mg
(n = 550)
Placebo
(n = 531)
   Wound problem
152 (28%)
162 (31%)
   Drowsiness/sedation
112 (20%)
122 (23%)
   Headache
49 (9%)
27 (5%)
   Hypoxia
49 (9%)
35 (7%)
   Pyrexia
45 (8%)
34 (6%)
   Dizziness
36 (7%)
34 (6%)
   Gynecological disorder
36 (7%)
33 (6%)
   Anxiety/agitation
33 (6%)
29 (5%)
   Bradycardia
32 (6%)
30 (6%)
   Shiver(s)
28 (5%)
30 (6%)
   Urinary retention
28 (5%)
18 (3%)
   Hypotension
27 (5%)
32 (6%)
   Pruritus
27 (5%)
20 (4%)
Preliminary observations in a small number of subjects suggest a higher incidence of headache when ondansetron orally disintegrating tablets are taken with water, when compared to without water.

Observed During Clinical Practice


In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of oral formulations of ondansetron. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron.

Cardiovascular:
Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT interval prolongation have been reported.

General:
Flushing. Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylaxis/anaphylactoid reactions, angioedema, bronchospasm, shortness of breath, hypotension, laryngeal edema, stridor) have also been reported. Laryngospasm, shock, and cardiopulmonary arrest have occurred during allergic reactions in patients receiving injectable ondansetron.

Hepatobiliary:
Liver enzyme abnormalities

Lower Respiratory:
Hiccups

Neurology:
Oculogyric crisis, appearing alone, as well as with other dystonic reactions

Skin:
Urticaria

Special Senses: Eye Disorders:
Cases of transient blindness, predominantly during intravenous administration, have been reported. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours.

DRUG ABUSE AND DEPENDENCE


Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

OVERDOSAGE


There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. Individual intravenous doses as large as 150 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events. These doses are more than 10 times the recommended daily dose.

In addition to the adverse events listed above, the following events have been described in the setting of ondansetron overdose: “Sudden blindness” (amaurosis) of 2 to 3 minutes’ duration plus severe constipation occurred in 1 patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension (and faintness) occurred in a patient that took 48 mg of ondansetron hydrochloride tablets. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed. In all instances, the events resolved completely.

DOSAGE AND ADMINISTRATION

Instructions for Use/Handling Ondansetron Orally Disintegrating Tablets


Do not attempt to push ondansetron orally disintegrating tablets through the foil backing. With dry hands, remove the tablet from the bottle or PEEL BACK the foil backing of 1 blister and GENTLY remove the tablet.  IMMEDIATELY place the ondansetron orally disintegrating tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary.

Prevention of Nausea and Vomiting Associated With Highly Emetogenic Cancer Chemotherapy


The recommended adult oral dosage of ondansetron orally disintegrating tablets is 24 mg given as three 8 mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin ≥50 mg/m2. Multiday, single-dose administration of a 24 mg dosage has not been studied.

Pediatric Use


There is no experience with the use of a 24 mg dosage in pediatric patients.

Geriatric Use


The dosage recommendation is the same as for the general population.

Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy


The recommended adult oral dosage is one 8 mg ondansetron orally disintegrating tablet given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8 mg  ondansetron orally disintegrating tablet should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

Pediatric Use


For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4 mg ondansetron orally disintegrating tablet given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4 mg ondansetron orally disintegrating tablet should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

Geriatric Use


The dosage is the same as for the general population.

Prevention of Nausea and Vomiting Associated With Radiotherapy, Either Total Body Irradiation, or Single High-Dose Fraction or Daily Fractions to the Abdomen


The recommended oral dosage is one 8 mg ondansetron orally disintegrating tablet given 3 times a day.

For total body irradiation
, one 8 mg ondansetron orally disintegrating tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.

For single high-dose fraction radiotherapy to the abdomen
, one 8 mg ondansetron orally disintegrating tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.

For daily fractionated radiotherapy to the abdomen
, one 8 mg ondansetron orally disintegrating tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.

Pediatric Use


There is no experience with the use of ondansetron orally disintegrating tablets in the prevention of radiation-induced nausea and vomiting in pediatric patients.

Geriatric Use


The dosage recommendation is the same as for the general population.

Postoperative Nausea and Vomiting


The recommended dosage is 16 mg given as two 8 mg ondansetron orally disintegrating tablets 1 hour before induction of anesthesia.

Pediatric Use


There is no experience with the use of ondansetron orally disintegrating tablets in the prevention of postoperative nausea and vomiting in pediatric patients.

Geriatric Use


The dosage is the same as for the general population.

Dosage Adjustment for Patients With Impaired Renal Function


The dosage recommendation is the same as for the general population. There is no experience beyond first-day administration of ondansetron.

Dosage Adjustment for Patients With Impaired Hepatic Function


In patients with severe hepatic impairment (Child-Pugh2 score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life. In such patients, a total daily dose of 8 mg should not be exceeded.

HOW SUPPLIED


Ondansetron Orally Disintegrating Tablets USP, 4 mg are white to off-white, round tablets debossed with ‘5’ on one side and ‘E’ on the other side with an embossed circular edge.
 
            Bottles of 10000                       NDC 65862-390-19
            3 x 10 Unit-dose Tablets           NDC 65862-390-10
       
Ondansetron Orally Disintegrating Tablets USP, 8 mg are white to off-white, round tablets debossed with ‘7’ on one side and ‘E’ on the other side with an embossed circular edge.
      
            Bottles of 6000                         NDC 65862-391-66
            3 x 10 Unit-dose Tablets           NDC 65862-391-10

Store at
20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.

REFERENCES

 
  1. Britto MR, Hussey EK, Mydlow P, et al. Effect of enzyme inducers on ondansetron (OND) metabolism in humans. Clin Pharmacol Ther. 1997;61:228.
  2. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg. 1973;60:646-649.
  3. Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999;65:377-381.
  4. De Witte JL, Schoenmaekers B, Sessler DI, et al. Anesth Analg. 2001;92:1319-1321.
  5. Arcioni R, della Rocca M, Romanò R, et al. Anesth Analg. 2002;94:1553-1557.

Manufactured for:
Aurobindo Pharma USA, Inc.
2400 Route 130 North
Dayton, NJ 08810
 
Manufactured by:
Aurobindo Pharma Limited
Hyderabad–500 072, India
 
Revised: 12/2010

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg (10,000 Tablet Bottle)


NDC 65862-390-19
Ondansetron Orally
Disintegrating Tablets, USP

4 mg
Rx only             10,000 Tablets
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg (10,000 Tablet Bottle)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg Blister Carton (3 x 10 Unit-dose)


Rx only                                   NDC 65862-390-10
Ondansetron Orally Disintegrating Tablets, USP
4 mg
30 Tablets (3 blister cards each containing 10 tablets)
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 mg Blister Carton (3 x 10 Unit-dose)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg (6,000 Tablet Bottle)


NDC 65862-391-66
Ondansetron Orally
Disintegrating Tablets, USP

8 mg
Rx only             6,000 Tablets
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg (6,000 Tablet Bottle)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg Blister Carton (3 x 10 Unit-dose)


Rx only                                   NDC 65862-391-10
Ondansetron Orally Disintegrating Tablets, USP
8 mg
30 Tablets (3 blister cards each containing 10 tablets)
AUROBINDO
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 8 mg Blister Carton (3 x 10 Unit-dose)

ONDANSETRON 
ondansetron   tablet, orally disintegrating
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)65862-390
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
ONDANSETRON (ONDANSETRON) ONDANSETRON4 mg
Inactive Ingredients
Ingredient NameStrength
MANNITOL 
CROSPOVIDONE 
LACTOSE MONOHYDRATE 
CELLULOSE, MICROCRYSTALLINE 
ASPARTAME 
SILICON DIOXIDE 
MAGNESIUM STEARATE 
Product Characteristics
ColorWHITE (White to Off-white) Score no score
ShapeROUNDSize5mm
FlavorSTRAWBERRY, GUARANAImprint Code 5;E
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
165862-390-1910000 TABLET In 1 BOTTLENone
265862-390-103 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
210 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (65862-390-10)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA09046904/12/2010

ONDANSETRON 
ondansetron   tablet, orally disintegrating
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)65862-391
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
ONDANSETRON (ONDANSETRON) ONDANSETRON8 mg
Inactive Ingredients
Ingredient NameStrength
MANNITOL 
CROSPOVIDONE 
LACTOSE MONOHYDRATE 
CELLULOSE, MICROCRYSTALLINE 
ASPARTAME 
SILICON DIOXIDE 
MAGNESIUM STEARATE 
Product Characteristics
ColorWHITE (White to Off-white) Score no score
ShapeROUNDSize7mm
FlavorSTRAWBERRY, GUARANAImprint Code 7;E
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
165862-391-666000 TABLET In 1 BOTTLENone
265862-391-103 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
210 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (65862-391-10)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA09046904/12/2010

Labeler - Aurobindo Pharma Limited (650082092)
Establishment
NameAddressID/FEIOperations
Aurobindo Pharma Limited918917642MANUFACTURE
Revised: 12/2010Aurobindo Pharma Limited